What happened with JANX today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Janux Therapeutics is developing treatments for cancer and autoimmune diseases, rather than selling approved medicines. Its early human trials include JANX007 for advanced prostate cancer, JANX008 for several solid tumors, and JANX011, an autoimmune-disease program being studied in healthy volunteers. None of its candidates is approved for sale, and it has never earned product-sales revenue.
All revenue to date has come from collaborations with Merck and BMS. These drugmakers receive exclusive license rights to specified candidates, while Janux can earn payments for research and product supply, development milestones, and royalties if resulting medicines reach the market. Janux has completed its research services for Merck, so that research funding has ended. Further collaboration income depends on the partners continuing their programs and candidates reaching agreed milestones.
Janux needs additional capital to complete development and commercialization. It relies on outside manufacturers, including WuXi Biologics, its principal supplier of critical biological materials. Selling medicines ultimately requires clinical evidence of safety and effectiveness and approval from the FDA or the relevant foreign regulator.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Vir Biotechnology competes directly with Janux’s JANX007: both develop masked drugs that recruit T cells against PSMA in prostate cancer. Watch VIR-5500’s development and Vir’s pending agreement with Astellas to share development costs and, if approved, U.S. profits and losses.
Xilio Therapeutics gives Janux a direct rival in masked drugs that recruit T cells against PSMA in prostate cancer. Progress in Xilio’s PSMA program will offer a comparison for JANX007 against a competing approach designed to stay inactive until activated within tumors.
CytomX Therapeutics competes with Janux on cancer immunotherapies designed to activate at tumors while limiting harm to healthy tissue. Its PROBODY results provide a comparison for that approach: the platform masks a drug’s binding site until enzymes in the tumor release it.
Xencor’s clinical safety and efficacy results are relevant to Janux because both develop antibodies that recruit T cells against solid tumors. Xencor earns upfront payments, milestones and royalties from partners that license its drug candidates; its solid-tumor antibody trials are the closer comparison for Janux’s pipeline.
Merck pays Janux for exclusive worldwide rights to two cancer programs that recruit T cells, giving Janux collaboration revenue before it has product sales. Janux recognized $10.0 million from this agreement in 2025; continued development matters for potential milestone payments and royalties on future sales.
Bristol Myers Squibb contributes to Janux’s revenue by obtaining exclusive rights to specified drug candidates, with potential milestone payments and royalties. Watch whether this medicine developer continues the collaboration: stopping it would cost Janux payments it might otherwise receive and could force it to seek funding elsewhere.
Novartis’s marketed Pluvicto gives Janux’s JANX007 an established treatment benchmark in PSMA-positive metastatic castration-resistant prostate cancer.
Amgen is ahead of Janux in bringing drugs that recruit T cells against solid tumors to market, providing both clinical and commercial benchmarks. Amgen sells medicines to healthcare providers and wholesalers; results from its approved solid-tumor T-cell engager and additional candidates are the relevant comparison for Janux’s still-unapproved pipeline.
MacroGenics competes with Janux in cancer antibodies that bind multiple targets and engage T cells. Its DART platform builds antibodies that bind two distinct targets; separately, collaborators fund its research and pay for drug-development and manufacturing services at its Maryland facility.
Telix Pharmaceuticals competes with Janux’s JANX007 for the metastatic castration-resistant prostate cancer treatment market through PSMA-targeted therapies. Watch its therapy-development progress rather than confuse it with current sales, which primarily come from Illuccix and Gozellix imaging agents supplied through commercial and hospital radiopharmacies.
Zymeworks competes with Janux in cancer treatments that bind multiple targets, including approaches that recruit T cells. Partners provide milestone payments and royalties to help fund its development; progress in its multispecific antibody pipeline is the part most relevant to Janux’s competing programs.
Fed Interest Rate Decision
Janux’s Fed-rate reading matters because higher interest rates can increase what it earns on its large cash and investment balances, while lower rates can reduce that interest income.
Expected4.0%Last release4.0%
If it comes in above expectations
Higher rates can lift the interest Janux earns on its cash and investments, adding to funds available to support research and development; the filing does not identify borrowing costs as a main business driver.
If it comes in below expectations
Lower rates can reduce the interest Janux earns on its cash and investments, leaving less income to support research and development; the filing does not identify borrowing costs as a main business driver.
Merck & Co., Inc. earningsMRK
If Merck’s report updates the cancer programs it licensed from Janux, readers can gauge whether those programs are advancing and whether Janux’s potential for future milestone payments and royalties remains in play.
Look for any disclosure that the two licensed programs remain in development and for signs of progress. Continued development could make future milestone payments or royalties more plausible, but would not guarantee payment; a pause or discontinuation would weaken that potential and leave Janux more reliant on its own capital or other partners. Merck’s research funding ended in August 2024, so continued development should not be mistaken for ongoing research-fee income.
Vir Biotechnology, Inc. earningsVIR
If Vir Biotechnology’s report updates VIR-5500, it will show how a competing masked PSMA-targeting T-cell engager for prostate cancer is progressing against JANX007.
Compare VIR-5500’s disclosed trial stage, progress, and safety or antitumor findings with what Janux has disclosed for JANX007; results from separate trials are not a head-to-head comparison. If VIR-5500 advances with encouraging data, a competing approach is moving forward and JANX007 will need to establish its value. Delays or disclosed safety or efficacy concerns could ease competitive pressure, but would not prove JANX007 works. The conclusion is whether patients in the same group may have a stronger alternative taking shape.
Janux Therapeutics, Inc. earningsThis company
Janux Therapeutics has no product sales yet, so this report will show whether its research spending is advancing JANX007 and JANX008 while its cash funds the work.
Read updates on JANX007 and JANX008 alongside research and development expense, operating cash use, and available cash. Progress with cash use still within the resources available would show capital moving the pipeline forward; rising costs without progress, or faster cash depletion, would make each next step more dependent on limited funds. The conclusion is whether Janux’s spending is buying clinical progress, not just a larger bill.
